The investigations have been led by the Barcelonaβeta Brain Research Center (BBRC) and have included participants without cognitive alterations from the ALFA Study, with the support of the ”la Caixa” Foundation
The Research Center of the Pasqual Maragall Foundation incorporates Dr. Argimon to lead the development and management of its research infrastructures, studies and cohorts.
The results, published in The New England Journal of Medicine, confirm that lecanemab slows cognitive decline by 27% in patients in the early stages of Alzheimer's disease.
The BBRC researcher and group leader gave a presentation on sources of variability in quantitative amyloid PET metrics
A study led by the Hospital del Mar Medical Research Institute, the Barcelonaβeta Brain Research Centre and the University of Gothenburg has compared the validity of nine biomarkers for the day-to-day diagnosis of Alzheimer's disease in hospital centres.
The research, within the European project EPAD, is headed by the Barcelonaβeta Brain Research Center (BBRC), a research center of the Pasqual Maragall Foundation, together with the University of Bristol.
The award is a recognition of the trajectory of the researcher, recipient in addition to a Knowledge Generation Project 2021
In the research, led by the BBRC, 250 people without cognitive alterations from the ALFA Study, promoted by the ”la Caixa” Foundation, have participated.
The consortium has officially ended its formal operation after six years of joint efforts and collaboration.